Tiziana Life Sciences Granted FDA Fast Track Designation

Contributed by: GlobeNewswire

Tags

FDA Fast Track

More Like This

FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclerosis

Tiziana Life Sciences Files for Orphan Drug Designation for Intranasal Foralumab

Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program

Tiziana Life Sciences Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis

Tiziana Life Sciences Submits Grant Application to ALS Association to Fund Clinical Trial of Intranasal Foralumab

Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis

Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

Tiziana Life Sciences Announces Groundbreaking ALS Trial Grant Awarded by the ALS Association